Key result
A high SAMe-TT2R2 score (>2) in warfarin-treated patients with acute VTE was associated with more frequent poor warfarin control (TTR <60%: 63.4% vs 52.3%, p<0.0001) and increased adverse events.
Why the study?
Does a high SAMe-TT2R2 score predict poor warfarin control and adverse events in patients with acute venous thromboembolism?
Cohort (n=1,943)
Does a high SAMe-TT2R2 score predict poor warfarin control and adverse events in patients with acute venous thromboembolism?
Absolute Event Rate: 63.4% vs 52.3%
p-value: p=<0.0001
The SAMe-TT2R2 score has modest predictive ability for identifying warfarin-treated VTE patients at risk for poor INR control and adverse clinical events.
High SAMe-TT2R2 score was associated with low TTR in acute VTE; extends AF data but leaves clinical utility open.
A high SAMe-TT 2 R 2 score predicted poor warfarin control and adverse events among atrial fibrillation patients. However, the SAMe-TT 2 R 2 score has not been well validated in venous thromboembolism (VTE) patients. A cohort of 1943 warfarin-treated patients with acute VTE was analyzed to correlate the SAMe-TT 2 R 2 score with time in therapeutic range (TTR) and clinical adverse events. A TTR <60% was more frequent among patients with a high (>2) versus low (0–1) SAMe-TT 2 R 2 score (63.4% vs 52.3%, p<0.0001). A high SAMe-TT 2 R 2 score (>2) correlated with increased overall adverse events (7.9 vs 4.5 overall adverse events/100 patient years, p=0.002), driven primarily by increased recurrent VTE rates (4.2 vs 1.5 recurrent VTE/100 patient years, p=0.0003). The SAMe-TT 2 R 2 score had a modest predictive ability for international normalized ratio (INR) quality and adverse clinical events among warfarin-treated VTE patients. The utility of the SAMe-TT 2 R 2 score to guide clinical decision-making remains to be investigated.
No takes yet. Share an insight, caveat, or question.
Kataruka et al. (2017) conducted a cohort in Acute venous thromboembolism (VTE) (n=1,943). High SAMe-TT2R2 score (>2) vs. Low SAMe-TT2R2 score (0-1) was evaluated on Time in therapeutic range (TTR) <60% (p=<0.0001). A high SAMe-TT2R2 score (>2) in warfarin-treated patients with acute VTE was associated with more frequent poor warfarin control (TTR <60%: 63.4% vs 52.3%, p<0.0001) and increased adverse events.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: